Full Press Release Details
IDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma.
IDYA
IDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
Key Takeaway: IDEAYA Announces First Patient In for Phase I Clinical Trial to Evaluate Darovasertib Monotherapy in Neo Adjuvant Uveal Melanoma
Price reaction · baseline $9.38 (2022-09-02 close) · hit after-hours · clean, no other IDYA news in the window
day 0 close
-1.5%
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+47%
120-day peak, hindsight
Typical move
5.2%
average across 6 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
IDE892
Phase 1 · NSCLC Adenocarcinoma